Fiche société
IGC Pharma, LLC
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications0liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| IGC-AD1-ActiveThe purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's. | Alzheimer | Phase 2 | À vérifier | United States, Canada, Puerto Rico | À vérifier |
| IGC-AD1-ActiveThe purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's. | Alzheimer | Phase 2 | À vérifier | United States, Canada, Puerto Rico | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| IGC-AD1-Active | Alzheimer | Phase 2 | NCT05543681 | CALMA — Clinical Trial on Agitation in Alzheimer's Dementia | ACTIVE_NOT_RECRUITING |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||